Current Report Filing (8-k)
October 12 2022 - 7:51AM
Edgar (US Regulatory)
false000113341600011334162022-10-122022-10-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 12, 2022
GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Nevada
|
001-31791
|
04-3562325
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
4960 PEACHTREE INDUSTRIAL BOULEVARD,
STE 240
NORCROSS, GA 30071
(Address of principal executive office) (zip code)
Registrant’s telephone number, including area code: (678) 620-3186
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock $0.001 par value per share
|
GALT
|
The Nasdaq Stock Market
|
Item 8.01 Other Items.
On October 12, 2022, Galectin
Therapeutics Inc. (the “Company) issued the press release attached hereto as Exhibit 99.1.
SECTION 9
|
— FINANCIAL STATEMENTS AND EXHIBITS
|
Item 9.01 Financial Statements and Exhibits.
|
(d) |
Exhibits. The following
exhibit is filed with this Report:
|
|
|
Description
|
|
|
|
|
|
Press release
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
|
Galectin Therapeutics Inc.
|
|
|
|
|
Date:
|
October 12, 2022
|
By:
|
/s/ Jack W. Callicutt
|
|
|
|
Jack W. Callicutt
Chief Financial Officer
|
- 3 -
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jul 2023 to Jul 2024